A review of the diagnosis, prevention, and treatment methods of inflammatory bowel disease

Seyed Saeid Seyedian, Forogh Nokhostin, Mehrdad Dargahi Malamir, Seyed Saeid Seyedian, Forogh Nokhostin, Mehrdad Dargahi Malamir

Abstract

Ulcerative colitis (UC) and Crohn's disease (CD) are classified as chronic inflammatory bowel diseases (IBD) which have similar symptoms and lead to digestive disorders and inflammation in the digestive system. The reason why they occur is still a mystery. A number of factors can be attributed to the prevalence of CD and UC, some of which include geographical location, inappropriate diet, genetics, and inappropriate immune response. Both diseases are more often diagnosed in urban areas compared to rural areas and both have their own challenges and side effects, but the patients can still have a good quality of life. Given the fact that the prevalence of this disease is higher at younger ages and that it disrupts half the life of the patient, it will, most likely, become a major health problem in the near future, even in developing countries. By reviewing valid scientific resources and evaluating new methods of addressing this disease, the present study aims to provide researchers and patients with new insights into this field and facilitate access to new treatments.

Keywords: Crohn’s disease (CD); IBD treatment; Inflammatory Bowel Disease (IBD); ulcerative colitis (UC).

Figures

Figure 1:
Figure 1:
Treatment proposed by Mesuri et al. (1994) for Crohn’s disease.

References

    1. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving treatments. The Lancet. 2007;369(9573):1641–57.
    1. Gryboski JD. Ulcerative colitis in children 10 years old or younger. J Pediatr Gastroenterol Nutr. 1993;17:24–31.
    1. Hugot JP, Corinne A, Dominique B, Edouard B, Cezard JP. Crohn’s disease: the cold chain hypothesis. Lancet. 2003;362:2012–15.
    1. Burgmann T, Clara I, Graft L, Walker J, Lix L, Rawsthorne P, et al. The Manitoba Inflammatory Bowel Disease Cohort study: Prolonged symptoms before diagnosishow much is irritable bowel syndrome? Clin Gastroenterol Hepatol. 2006;4:614–20.
    1. Farmer RG, Hawk WA, Turnbull RB., Jr. Clinical patterns in Crohn’s disease: A statistical study of 615 cases. Gastroenterology. 1975;68:627–35.
    1. Mehdizadeh S, Chen G, Enayati PJ, Cheng DW, Han NJ, Shaye OA, et al. Diagnostic yield of capsule endoscopy in ulcerative colitis and inflammatory bowel disease of unclassified type (IBDU) Endoscopy. 2008;40:30–5.
    1. Yang C, Singh P, Singh H, Le ML, El-Matary W. Systematic review: thalidomide and thalidomide analogues for treatment of inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. 2015;41(11):1079–93.
    1. Baldassano RN, Piccoli DA. Inflammatory bowel disease in pediatric and adolescent patients. Gastroenterol Clin North Am. 1999;28(2):445–58.
    1. Cummings JF, Keshav S, Travis SP. Medical management of Crohn’s disease. BMJ. 2008;336(7652):1062.
    1. Tremaine WJ. Diagnosis and treatment of indeterminate colitis. Gastroenterology & hepatology. 2011;7(12):826.
    1. Guindi M, Riddell R. Indeterminate colitis. J Clin Pathol. 2004;57(12):1233–44.
    1. Nikolaus S, Schreiber S. Diagnostics of Inflammatory Bowel Disease. Gastroenterology. 2007;133:1670–89.
    1. Askling J, Grahnquist L, Ekbom A, Finkel Y. Prevalence of pediatrics Crohn’s disease in Stockholm, Sweden. Lancet. 1999;354:1179.
    1. Kugathasan S, Judd RH, Hoffmann RG, Heikenen J, Telega G, Khan F, et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide populationbased study. J Pediatr. 2003;143:525–31.
    1. Mikaeli J, Nobakht M, Sotudeh M, Malekzadeh R. Crohn’s Disease: A review of 140 cases from Iran. Irn J Med Sci. 2000;25:138–43.
    1. Ghavami A, Saidi F. Pattern of colonic disorders in Iran. Dis Colon Rectum. 1969;12:462–68.
    1. Mir-Madjlessi SH, Forouzandeh B, Ghadimi R. Ulcerative Colitis in Iran: A Review of 112 Cases. The American J Gastroentero. 1985;80:862–5.
    1. Feshareki R, Soleimany H. Crohn’s Disease in Isfahan. Report of a case. Pahlavi Medical Journal. 1976;7:565–75.
    1. Norouzpour A, Khoshdel AR, Modaghegh MH, Kazemzadeh GH. Prehospital management of gunshot patients at major trauma care centers: exploring the gaps in patient care. Trauma Mon. 2013;18(2):62–6.
    1. Aghazadeh R, Zali MR, Bahari A, Amin K, Ghahghaie F, Firouzi F. Inflammatory bowel disease in Iran: a review of 457 cases. J Gastroenterol Hepatol. 2005;20(11):1691–5.
    1. Malekzadeh F, Alberti C, Nouraei M, Vahedi H, Zaccaria I, Meinzer U, et al. Crohn’s disease and early exposure to domestic refrigeration. PLoS ONE. 2009;4 e4288.
    1. Vahedi H, Momtahan S, Kazzazi AS, Olfati G, Nasseri-Moghaddam S, Tabrizian T, et al. Establishment of a wide registry in patients with inflammatory bowel disease referred to several clinics in Tehran from 2004-2007. Govaresh. 2007;12S:48–9.
    1. Molinie F, Gower-Rousseau C, Yzet T, Merle V, Grandbastien B, Marti R, et al. Opposite evolution in prevalence of Crohn’s disease and ulcerative colitis in Northern France (1988–1999) Gut. 2004;53:843–8.
    1. Mayberry J, Mann R. Inflammatory bowel disease in rural sub-Saharan Africa: rarity of diagnosis in patients attending mission hospitals. Digestion. 1989;44:172–6.
    1. Acheson ED. The distribution of ulcerative colitis and regional enteritis in United States veterans with particular reference to the Jewish religion. Gut. 1960;1:291–3.
    1. Grossman A, Fireman Z, Lilos P, Novis B, Rozen P, Gilat T. Epidemiology of ulcerative colitis in the Jewish population of central Israel 1970-1980. Hepatogastroenterology. 1989;36:193–7.
    1. Heyman MB, Kirschner BS, Gold BD, Ferry G, Baldassano R, Cohen SA, et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr. 2005;146:35–40.
    1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417–29.
    1. Dickinson RJ, Varian SA, Axon AT, Cooke EM. Increased prevalence of faecal coliforms with in vitro adhesive and invasive properties in patients with ulcerative colitis. Gut. 1980;21:787–972.
    1. Marteau P, Lepage P, Mangin I, Suau A, Doré J, Pochart P, et al. Review article: gut flora and inflammatory bowel disease. Aliment Pharmacol Ther. 2004;20(4):18–23.
    1. Hampe J, Grebe J, Nikolaus S, Solberg C, Croucher PJ, Mascheretti S, et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn’s disease: A cohort study. Lancet. 2002;359:1661–5.
    1. Corrao G, Tragnone A, Caprilli R, Trallori G, Papi C, Andreoli A, et al. Risk of inflammatory bowel disease attributable to smoking, oral contraception and breastfeeding in Italy: a nationwide case-control study. Cooperative Investigators of the Italian Group for the Study of the Colon and the Rectum (GISC) Int J Epidemiol. 1998;27:397–404.
    1. Koletzko S, Griffiths A, Corey M, Smith C, Sherman P. Infant feeding practices and ulcerative colitis in childhood. BMJ. 1991;302:1580–1.
    1. Montgomery SM, Morris DL, Pounder RE, Wakefield AJ. Paramyxovirus infections in childhood and subsequent inflammatory bowel disease. Gastroenterology. 1999;116:796–803.
    1. Wakefield AJ, Ekbom A, Dhillon AP, Pittilo RM, Pounder RE. Crohn’s disease: pathogenesis and persistent measles virus infection. Gastroenterology. 1995;108:911–6.
    1. Ekbom A, Wakefield AJ, Zack M, Adami HO. Perinatal measles infection and subsequent Crohn’s disease. Lancet. 1994;344:508–10.
    1. Davis RL, Kramarz P, Bohlke K, Benson P, Thompson RS, Mullooly J, et al. Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease: a case-control study from the Vaccine Safety Datalink project. Arch Pediatr Adolesc Med. 2001;155:354–9.
    1. Thornton JR, Emmett PM, Heaton KW. Diet and Crohn’s disease: characteristics of the pre-disease diet. Br Med J. 1979;2:762–4.
    1. Belluzzi A, Brignola C, Campieri M, Pera A, Boschi S, Miglioli M. Effect of an enteric-coated fish-oil preparation on relapses in Crohn’s disease. N Engl J Med. 1996;334:1557–60.
    1. Hartmann G, Endres S. n-3 polyunsaturated fatty acids and human cytokine synthesis. In: Yehoda S, Mostofsky D, editors. Handbook of Essential Fatty Acid Biology: Biochemistry, Physiology, ad Behavioral Biology. Totawa: Humana Press; 1997. p. 103.
    1. Lashner BA, Kane SV, Hanauer SB. Lack of association between oral contraceptive use and Crohn’s disease: a community-based matched case-control study. Gastroenterology. 1989;97:1442–7.
    1. Forbes A, Kalantzis T. Crohn’s disease: the cold chain hypothesis. Int J Colorectal Dis. 2006;21:399–401.
    1. Andersson RE, Olaison G, Tysk C, Ekbom A. Appendectomy and protection against ulcerative colitis. N Engl J Med. 2001;344:808–14.
    1. Ahmad NA, Iqbal N, Joyce A. Clinical impact of capsule endoscopy on management of gastrointestinal disorders. Clin Gastroenterol Hepatol. 2008;6:433–7.
    1. Singh B, McC, Mortensen N, Jewell D, George B. Perianal Crohn’s disease. BJS. 2004;91(7):801–14.
    1. Travis S, Stange E, Lémann M, Öresland T, Chowers Y, Forbes A, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut. 2006;55(1):116–35.
    1. Von Roon AC, Karamountzos L, Purkayastha S, Reese GE, Darzi AW, Teare JP, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007;102(4):803.
    1. Lewis JD. C-reactive protein: anti-placebo or predictor of response. Gastroenterology. 2005;129(3):1114–6.
    1. Gisbert JP, Bermejo F, Pérez-Calle J-L, Taxonera C, Vera I, McNicholl AG, et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis. 2009;15(8):1190–8.
    1. Mow WS, Vasiliauskas EA, Lin YC, Fleshner PR, Papadakis KA, Taylor KD, et al. Association of antibody responses to microbial antigens and side effects of small bowel Crohn’s disease. Gastroenterology. 2004;126:414–24.
    1. Bernstein CN. ExtraBowel manifestations of inflammatory bowel disease. Current gastroenterology reports. 2001;3(6):477–83.
    1. Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case control study. Aliment Pharmacol Ther. 2000;14:145–53.
    1. Nugent FW, Roy MA. Duodenal Crohn’s disease. An analysis of 89 cases. Am J Gastroenterol. 1989;84:249–54.
    1. Danovitch SH. Fulminant colitis and toxic megacolon. Gastroenterol Clin North Am. 1989;18:73–82.
    1. Ng SC, Kamm MA. Therapeutic strategies for the management of ulcerative colitis. Inflamm Bowel Dis. 2008
    1. Wheeler JG, Slack NF, Dancan A, Whitehead PJ, Russell G, Harvey RF. The diagnosis of intraabdominal abscesses in patients with severe Crohn’s disease. Q J Med. 1992;82:159–67.
    1. Feldman Paul A, MD, Wolfson Daniel, MD, Barkin Jamie S., MD Medical Management of Crohn’s Disease. Clin Colon Rectal Surg. 2007;20(4):269–281.
    1. Andrews JM, Travis SP, Gibson PR, Gasche C. Systematic review: does concurrent treatment with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes? Aliment Pharmacol Ther. 2009;29:459–69.
    1. Kruis W, Kiudelis G, Rácz I, Gorelov IA, Pokrotnieks J, Horynski M, et al. International Salofalk OD Study Group Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blined, double- dummy, randomized, non-inferiority trial. Gut. 2009;58:233–40.
    1. Ford AC, Achkar J-P, Khan KJ, Kane SV, Talley NJ, Marshall JK, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):601.
    1. Marshall JK, Thabane M, Steinhart AH, Newman JR, Anand A, Irvine EJ. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. 2010
    1. Hanauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn’s disease: a meta-analysis of doubleblind, placebo-controlled trials. Clin Gastroenterol Hepatol. 2004;2:379–88.
    1. Messori A, Brignola C, Trallor G, Rampazzo R, Bardazzi G, Belloli C, et al. Effectiveness of 5-aminosalicylic acid for maintaining remission in patients with Crohn’s disease: A meta-analysis. Am J Gastroenterol. 1994;89:692–8.
    1. Jorgensen LG, Fredholm L, Petersen PH, et al. How accurate are clinical activity indices for scoring of disease activity in inflammatory bowel disease (IBD)? Clin Chem Lab Med. 2005;43:403–411.
    1. Loftus CG, Loftus EV, Harmsen WS, et al. Update on the prevalence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. Inflamm Bowel Dis. 2007;13:254–261.
    1. Kataoka H, Kamiya T, Joh T. The first case of biological treatment discontinuation after a complete remission induced by maintenance treatment with adalimumab for refractory ulcerative colitis. J Clin Med Res. 2015;7:118–121. [PMID: 25436030 doi: 10.14740/ jocmr1991w].
    1. Siegel Corey A. What Options Do We Have for Induction Treatment for Crohn’s Disease? Dig Dis. 2010;28(3):543–547.
    1. Tanida S, Mizoshita T, Ozeki K, Katano T, Kataoka H, Kamiya T, Joh T. Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2. World J Gastroenterol. 2015;21(29):8776–8786. Retrieved from: URL: doi: .
    1. Van Assche G, Vermeire S, Rutgeerts P. Treatment of severe steroid refractory ulcerative colitis. World J Gastroenterol. 2008;14:5508–11.
    1. Cima RR, Pemberton JH. Medical and surgincal management of chronic ulcerative colitis. Arch Surg. 2005;140:300–10.
    1. Zachos M, Tondeur M, Griffiths AM. Enteral nutrition treatment for induction of remission in Crohn’s disease. Cochrane Database Syst Rev. 2000;(1) CD000542.
    1. Middleton SJ, Naylor S, Woolner J, Hunter JO. A doubleblind, randomized, placebo-controlled trial of essential fatty acid supplementation in the maintenance of remission of ulcerative colitis. Aliment Pharmacol Ther. 2002;16:1131–5.
    1. Garcia Rodriguez LA, Ruigomez A, Panes J. Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. Gastroenterology. 2006;130:1588–1594.
    1. Gradel KO, Nielsen HL, Schonheyder HC, Ejlertsen T, Kristensen B, Nielsen H. Increased short- and long-term risk of inflammatory bowel disease after salmonella or Campylobacter gastroenteritis. Gastroenterology. 2009;137:495–501.
    1. Duigenan S, Gee MS. Imaging of pediatric patients with inflammatory bowel disease. AJR Am J Roentgenol. 2012;199:907–915.
    1. Afaf M, Azza E-M, Ali M, et al. Azithromycin and erythromycin ameliorate the extent of colonic damage induced by acetic acid in rats. Toxicology and Applied Pharmacology. 2005;205:43–52.
    1. Remo Chadwick W, Subrata G, Kevin R. Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease. Ther Adv Gastroenterol. 2011;4(4):237–248.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する